Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Condition:   Pain, Acute Interventions:   Drug: Fixed Dose Combination;   Drug: Etodolac;   Drug: Cyclobenzaprine Sponsor:   Apsen Farmaceutica S.A. Not yet recruiting - verified April 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials